Vascular toxicity of antineoplastic agents

Seminars in Oncology

Volumn 33, Issue 1, 2006, Pages 121-138

  Shahab, Nasir ^a,b   Haider, Syed ^a   Doll, Donald C ^a  

^a University of Missouri   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IRINOTECAN; METHOTREXATE; MITOMYCIN; PACLITAXEL; PROCARBAZINE; TAMOXIFEN; TENIPOSIDE; TIOGUANINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ARTERY THROMBOSIS; ARTIFICIAL EMBOLISM; AUTONOMIC NEUROPATHY; BLOOD CLOTTING DISORDER; BUDD CHIARI SYNDROME; CANCER; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; HAND FOOT SYNDROME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HISTOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOCYTOCLASTIC VASCULITIS; LIVER VEIN OBSTRUCTION; LUNG EMBOLISM; LUNG VEIN OBSTRUCTION; PATHOGENESIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; RETINA DISEASE; REVIEW; RISK FACTOR; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULAR DISEASE;

EID: 32244438331     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.11.006     Document Type: Article

References (447)

1. E.A. Bastounis, A.J. Karayiannakis, G.G. Makri The incidence of occult cancer in patients with deep vein thrombosis A prospective study J Intern Med 239 1996 153 156
2. M. Monreal, J. Fernandez-Liamazares, J. Perandreu Occult cancer in patients with venous thromboembolism Which patients, which cancer? Throm Haemost 78 1997 1316 1318
3. P. Prandorti, A.W.A. Lensing, H.R. Buller Deep-vein thrombosis and the incidence of subsequent symptomatic cancer N Engl J Med 327 1992 1128 1133
4. D.C. Doll, J.W. Yarbro Vascular toxicity associated with antineoplastic agents Semin Oncol 19 1992 580 596
5. D.C. Doll, J.W. Yarbro Vascular toxicity associated with chemotherapy and hormonotherapy Curr Opin Oncol 6 1994 345 350
6. C.A. Wagevoort Pulmonary veno-occlusive disease. Entity or syndrome? Chest 69 1997 82 86
7. V. Thadany, C. Burrow, W. Whitaker Pulmonary veno-occlusive disease Q J Med 44 1975 133 156
8. G. Corrin, H. Spencer, M. Turner-Warwich Pulmonary veno-occlusion An immune complex disease? Virchows Arch 364 1974 81 91
9. A.G. Rose Pulmonary veno-occlusive disease due to bleomycin therapy for lymphoma South Afr Med J 64 1983 636 638
10. R. Joselson, M. Warnock Pulmonary veno-occlusive disease after chemotherapy Hum Pathol 13 1983 88 91
11. R.E. Waldhorn, E. Tsou, F.P. Smith Pulmonary veno-occlusive disease associated with niicroangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma Med Pediatr Oncol 12 1984 394 396
12. C.M. Lombard, A. Churg, S. Winokur Pulmonary veno-occlusive disease following therapy for malignant neoplasms Chest 92 1987 871 876
13. Sj. Capewell, Aj. Wright, D.A. Ellis Pulmonary veno-occlusive disease in association with Hodgkin's disease Thorax 39 1984 554 555
14. X. Troussard, J.F. Bemaudin, C. Cordonnier Pulmonary veno-occlusive disease after bone marrow transplantation Thorax 39 1984 956 957
15. S.A. Giralt, C.F. LeMaistre, H.M. Vriesendorp Etoposide, cyclophosphamide, total body irradiation, and allogenic bone marrow transplantation for hematologic malignancies J Clin Oncol 12 1990 1923 1930
16. G.C. Steward, I. Pellier, A. Mahajan Severe pulmonary hypertension a frequent complication of stem cell transplantation for malignant infantile osteoporosis Br J Haematol 124 2004 63 71
17. C. Bruckman, W. Linder, R. Roos Severe pulmonary vascular occlusive disease following bone marrow transplantation Eur J Transplant 150 1991 242 245
18. J.E. Sanderson, S.G. Spiro, A.T. Hendry A case of pulmonary veno-occlusive disease responding to treatment with azathioprine Thorax 32 1977 140 148
19. S. Zafrani, Y. Pinaudeau, D. Dhumeaux Drug-induced vascular lesions of the liver Arch Intern Med 143 1983 495 502
20. G. Bras, D.B. Jelliffe, K.L. Stuart Veno-occlusive disease of liver with non-portal type of cirrhosis occuring in Jamaica Arch Pathol Lab Med 57 1954 285 300
21. B.J. Rollins Hepatic veno-occlusive disease Am J Med 81 1986 297 306
22. L. Ledwig, E. Hashimoto, D.B. McGill Classification of hepatic venous outflow obstruction ambiguous terminology of the Budd-Chiari syndrome Mayo Clin Proc 65 1996 51 55
23. G.B. Reed Jr, A.J. Cox The human liver after radiation injury A form of veno-occlusive disease Am J Pathol 48 1966 597 611
24. Brodsky, H. Johnson, S.A. KiUmann Fibrosis of central and hepatic veins, and perisinusoidal spaces of the liver following prolonged administration of urethane 1 Am J Med 30 1961 976 980
25. P.F. Griner, A. Elbadawi, C.H. Packman Veno-occlusive disease of the liver after chemotherapy of acute leukemia Report of two cases Ann Intern Med 85 1976 578 582
26. R.A. Gill, G.R. Onstad, J.M. Cardamone Hepatic veno-occlusive disease caused by 6-thiioguanine Ann Intern Med 96 1982 58 60
27. J.P. Sloane, N.U.G. Farthing, P.L. Powles Histopathological changes in the liver after allogeneic bone marrow transplantation J Clin Pathol 33 1980 344 348
28. W.G. Woods, L.P. Dehner, M.E. Nesbit Fatal veno-occlusive disease of the liver following high dose chemotherapy, irradiation and bone marrow transplantation Am J Med 68 1980 285 290
29. A. Burkhardt, G. Kloppet Unusual obliterative disease of the hepatic veins in an infant Virchows Arch 375 1977 225 232
30. R.E. McIntyre, J.G. Magidson, G.E. Austin Fatal veno-occlusive disease of the liver following high-dose 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU) and autologous bone marrow transplantation Am J Clin Pathol 75 1981 614 617
31. G. Vassal, Hartmann, E. Benhamon Busulfan and veno-occlusive disease of the liver 0 Ann Intern Med 112 1991 881 (letter)
32. H.M. Shuhnan, G.B. McDonald, D. Matthews An analysis of hepatic veno-occlusive disease and centrilobular hepatic degeneration following bone marrow transplantation Cancer 79 1982 1178 1191
33. H.M. Lazarus, M.R. Gottfried, R.H. Herzig Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation Cancer 49 1982 1789 1795
34. M.R. Gottfried, O. Sudilovsky Hepatic veno-occlusive disease after high-dose mitomycin C and autologous bone marrow transplantation therapy Hum Pathol 13 1982 646 650
35. C. Erichsen, P.E. Jonsson Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma J Surg Oncol 27 1984 268 270
36. A.T. Marubbio, B. Danielson Hepatic veno-occlusive disease in a renal transplant patient receiving azathioprine Gastroenterology 69 1975 739 743
37. A.E. Read, R.H. Wiesner, D.R. LaBrecque Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy Ann Intern Med 104 1986 651 655
38. D.M. Green, J.Z. Finkelstein, P. Norkool Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine Cancer 62 1988 270 273
39. D.M. Green, P. Norkool, N.E. Breslow Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules A report from the National Wilms' Tumor Study J Clin Oncol 8 1990 1525 1530
40. J. Raine, A. Bownian, K. Wallendszus Hepatopathy-thrombocytopenia syndromes complication of dactinomycin therapy for Wilms' tumor. A report from the United Kingdom Children's Cancer Study Group J Clin Oncol 9 1991 268 273
41. J.A. Ortega, S.A. Donaldson, S.P. Ivy Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma Cancer 79 1997 2435 2439
42. V. Hazar, T. Kutluk, C. Akyuz Veno-occlusive disease-like hepatotoxicity in two children receiving chemotherapy for Wilms' tumor and clear cell sarcoma of kidney Pediatr Hematol Oncol 15 1998 85 89
43. S. Cubc, J. Kraker, D. Kuljis Fatal hepatic veno-occlusive disease with fibrinolysis as the cause of death during preoperative chemotherapy for nephroblastoma Med Pediatr Oncol 31 1998 175 176
44. M. Dobbie, S. Hofer, R. Oberholzer Veno-occlusive disease of the liver induced by gemcitabine Ann Oncol 9 1998 681 (letter)
45. C. Dumontet, F. Morschauser, P. Solal-Gelginy Gemcitabine as a single agent in the treatment of replased or refractory low grade non-Hodgkin's lymphoma Br J Haematol 113 2001 772 778
46. F.J. Giles, H.M. Kantarjian, S.M. Kornblau Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Cancer 92 2001 406 413
47. W.J. Kell, A.K. Burnett, R. Chopra A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute leukemia Blood 102 2003 4277 4283
48. P. Rajvanshi, H.M. Shulman, E.L. Sievers Hepatic sinusoidal obstruction after gemtuzumab ozogamicin therapy Blood 99 2002 2310 2314
49. S.I. Bearman The syndrome of hepatic veno-occlusive disease after marrow transplantation Blood 85 1995 3005 3020
50. G.B. McDonald, P. Sharma, D.E. Matthews Veno-occlusive disease of the liver after bone marrow transplantation Diagnosis, incidence, and predisposing factors Hepatology 4 1984 116 122
51. G.B. McDonald, M.S. Hinds, L.D. Fisher Veno-occlusive disease of the liver and multi-organ failure after bone marrow transplantation A cohort study of 355 patients Ann Intern Med 118 1993 255 267
52. J.H. Essel, J.M. Thompson, G.S. Harman Increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide Blood 79 1992 2782 2788
53. L.B. Grochow, R.J. Jones, R.B. Brundett Pharmacokinetics of busulfan Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 25 1989 55 61
54. E. Faioni, A. Krachmalnicoff, S.I. Bearman Naturally occurring anticoagulants and bone marrow transplantation plasma protein C predicts the development of venoocclusive disease of the liver Blood 81 1993 3458 3462
55. N. Frickhofen, M. Wiesneth, C. Jainta Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation Blood 83 1994 1998 2004
56. W.E. Beschomer, J. Pino, J.K. Boitnott Pathology of the liver with bone marrow transplantation Effects of busulfan, carmustine, acute graft-versus- host disease, and cytomegalovirus infection Am J Pathol 99 1980 369 386
57. L.J. Ayash, M. Hunt, K. Antman Thrombocytopenia in veno-occlusive disease in autologous bone marrow transplantation of solid tumors and lymphomas J Clin Oncol 8 1990 1699 1706
58. M.S. Anscher, W.P. Peters, H. Reisenbid-der Transforming growth factor P as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer N Engl J Med 328 1993 1592 1598
59. T. Murase, R.L. Jirtle, G.B. McDonald Transforming growth factor plasma concentrations in patients with leukemia and lymphoma receiving chemo radiotherapy and marrow transplantation Blood 83 1994 2383 2384 (letter)
60. L. Gugliotta, L. Catani, N. Vianelli High plasma levels of tumor necrosis factor-alpha may be predictive of veno-occlusive disease in bone marrow transplantation Blood 83 1994 2385 2386 (letter)
61. C. Salat, E. Holler, H.J. Kolb Plasminogen activator inhibitory confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation Blood 89 1997 2184 2188
62. B. Rio, G. Andreu, A. Nicod Thrombocytopenia in veno-occlusive disease after bone marrow transplantation or chemotherapy Blood 67 1986 1773 1776
63. K. Yoshimoto, K. Yahushiji, H. Ijuin Colour doppler ultrasonography of a segmental branch of the portal vein is useful for early diagnosis and monitoring of the therapeutic course of venoocclusive disease after allogenic haematopoietic stem cell transplantation Br J Haematol 115 2001 945 948
64. P. Richardson, E. Guinan The pathology, diagnosis and treatment of hepatic veno-occlusive disease Current status and novel approaches Br J Haematol 107 1999 485 493
65. A. Saviola, M. Luppi, L. Potenza Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogomicin Successful treatment with defibrotide Br J Haematol 123 2003 752 753 (letter)
66. S. Stoneham, L. Lennard, P. Coen Veno-occlusive disease in patients in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukemia Br J Haematol 123 2003 100 102
67. B. Piel, S. Vaidya, D. Lancaster Chronic hepatotoxicity following 6-thioguanine therapy for childhood acute lymphoblastic leukemia Br J Haematol 125 2004 410 411
68. M.D. Blostein, O.B. Paltiel, A. Thibault A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation Bone Marrow Transplant 10 1992 439 443
69. S.I. Bearman, G.L. Anderson, M. Mori Veno-occlusive disease of the liver Development of a model for predicting fatal outcome after marrow transplantation J Clin Oncol 11 1993 1729 1736
70. M. Eltani, P. Trivedi, J.R. Hobbs Monitoring of veno-occlusive disease after bone marrow transplantation by serum aminopropeptide of type III procollagen Lancet 342 1993 518 521
71. M. Attal, F. Huguet, H. Rubie Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin A prospective, randomized trial Blood 79 1992 2834 2840
72. J.H. Lee, K.H. Lee, J.H. Lee Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogenic bone marrow transplantation in adults conditioned with busulfan and cyclophosphamide Br J Haematol 118 2002 1087 1094
73. M. Heikinheimo, R. Halila, A. Fasth Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation Blood 83 1994 3036 3040
74. J.Y. Cahn, M. Flesch, A. Brion Prevention of veno-occlusive disease of the liver after bone marrow transplantation Heparin or no heparin? Blood 80 1992 2149 2150
75. J.A. Bianco, F.R. Appelbaum, J. Nemunaitis Phase I-II trial of pentoxifyline for the prevention of transplant-related toxicities following bone marrow transplantation Blood 78 1991 1205 1211
76. R.A. Clift, J.A. Bianco, F.R. Appelbaum A randomized controlled trial of pentoxifyline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation Blood 82 1993 2025 2030
77. M. Attal, F. Huguet, H. Rubie Prevention of regime-related toxicities after bone marrow transplantation by pentoxifyline A prospective, randomized trial Blood 82 1993 732 736
78. Bearman, D.D. Shen, M.S. Hinds A phase I/II study of prostaglandin El for the prevention of hepatic veno-occlusive disease after bone marrow transplantation 51 Br J Haematol 94 1993 727 730
79. E. Gluckman, L. Jolivet, M.L. Scrobohaci Use of prostaglandin El for prevention of liver veno-occlusive disease in leukemic patients treated by allogeneic bone marrow transplantation Br J Haematol 74 1990 277 281
80. J.H. Essell, M.T. Schroeder, G.S. Harrnan Ursodial prophylaxis against hepatic complications of allogeneic bone marrow transplantation Ann Intern Med 128 1998 975 981
81. T. Ruutu, B. Eriksson, K. Remes Urideoxycholic acid for the prevention of hepatic complications in allogenic stem cell transplantation Blood 100 2002 1977 1983
82. S.I. Bearman, M.C. Shuhart, M.S. Hinds Recombinant human tissue plasminogen activator for the treatment of established severe veno-occlusive disease of the liver after bone marrow transplantation Blood 80 1992 2458 2462
83. G. Rostic, G. Bandini, A. Belardinelli Alteptase for hepatic veno-occlusive disease after bone-marrow transplantation Lancet 339 1992 1481 1482
84. O. Ringden, L. Wennberg, B.G. Ericzon Alteplase for hepatic veno-occlusive disease after bone marrow transplantation Lancet 340 1992 546 547
85. S.I. Bearman, J.L. Lee, A.E. Baron Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients Blood 89 1997 1501 1506
86. W.D. Harie, L.C. Stephens, E.I. Ruby Antithrombin III treatment of organ dysfunction during bone marrow transplantation Results of a pilot study Blood 88 1996 458a (abstr)
87. S. Stasser, G. McDonald Gastrointestinal and hepatic complications S. Forman K. Blune E. Thomas Haematopoietic Cell Transplantation 1999 Blackwell Science Oxford, UK 1 127
88. H.J. Schitt, H.J. Tischler, B. Ringe Allogenic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation Clinical and immunological considerations Bone Marrow Transplant 16 1995 473 478
89. S. Coccheri, G. Biago Defibrotide Cardiovasc Drug Rev 9 1991 172 196
90. O.N. Ulutin Antithrombotic effect and clinical potential of defibrotide Semin Thromb Hemost 19 1993 186 191
91. R. Chopra, J.D. Eaton, A. Grassi Defibrotide for the treatment of hepatic veno-occlusive disease Results of European compassionate-use study Br J Haematol 111 2000 1122 1129
92. P.G. Richardson, C. Murakami, Z. Jin Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure Response without significant toxicity in a high risk population and factors predictive of outcome Blood 100 2002 4337 4343
93. M.A. Greenstone, P.M. Dowd, D.P. Nfikhailidis Hepatic vascular lesions associated with dacarbazine treatment Br Med J 282 1981 1744 1745
94. R.F. Asbury, S.N. Rosenthal, M.E. Descalzi Hepatic veno-occlusive disease due to DTIC Cancer 45 1980 2670 2674
95. A.N. Houghton, N. Shafi, F.R. Rickles Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease. A case report Cancer 44 1979 2324 2329
96. I.M. Lehrner, R.E. Enck Hepatic vein thrombosis after chemotherapy for histiocytoma Ann Intern Med 88 1977 575 576 (letter)
97. J.S. Wasser, M. Coleman Leukemia chemotherapy and centrilobular hepatic necrosis Ann Intern Med 86 1977 508 509 (letter)
98. N. Krivoy, R. Raz, A. Carter Reversible hepatic veno-occlusive disease and 6-thioguanine Ann Intern Med 96 1982 788 (letter)
99. H. Meindok, B. Langer Liver scan in Budd-Chiari syndrome J Nucl Med 17 1976 365 368
100. P.J. Frosch, B.M. Czametzki, E. Macher Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma J Cancer Res Clin Oncol 95 1979 281 286
101. W. Feaux de Lacroix, U. Runne, H. Hauk Acute liver dystrophy with thrombosis of hepatic veins A fatal complication of dacarbazine treatment Cancer Treat Rep 67 1983 779 784
102. H. Joensuu, K. Soderstrom, V. Mikkanen Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report -0 Cancer 58 1986 1437 1440
103. E. McClay, C.J. Lusch, M.J. Mastrangelo Allergy-induced hepatic toxicity associated with dacarbazine Cancer Treat Rep 71 1987 219 220 (letter)
104. G. Ceci, M. Bella, M. Melissani Fatal hepatic vascular toxicity of DTIC Is it really a rare event? Cancer 61 1988 1988 1991
105. B. Sundstrup Raynaud's phenomenon after bleomycin treatment Med J Aust 2 1978 266 (letter)
106. D. Adoue, P. Arlet Bleomycin and Raynaud's phenomenon Ann Intern Med 100 1984 770 (letter)
107. D. Malcolm Bleomycin-induced injury to the hands J Med Soc N J 75 1978 314 316
108. N.J. Vogelzang, G.J. Bosl, K. Johnson Raynaud's phenomenon A common toxicity after combination chemotherapy for testicular cancer Ann Intern Med 95 1981 288 292
109. C. Teutsch, A. Lipton, H.A. Harvey Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular cancer Cancer Treat Rep 61 1977 925 926
110. H. Rothberg Raynaud's phenomenon after vinblastine-bleomycin chemotherapy Cancer Treat Rep 62 1978 569 570 (letter)
111. A.R. Soble Chronic bleomycin-associated Raynaud's phenomenon Cancer Treat Rep 62 1978 570 (letter)
112. D.P. Chemicoff, R.M. Buiowski, J.R. Young Raynaud's phenomenon after bleomycin treatment Cancer Treat Rep 62 1978 570 571 (letter)
113. M.E. Schuten, C.G. Schmidt Raynaud's phenomenon and cancer chemotherapy Ann Intern Med 96 1982 256 (letter)
114. J.G. Paty Jr, B.W. Ruffner Bleomycin-vinblastine associated Raynaud's phenomenon J Rheumatol 7 1980 927 928 (letter)
115. N.J. Vogelzang Raynaud's phenomenon and cancer chemotherapy Ann Intern Med 96 1982 256 (letter)
116. J.J. Grau, M. Grau, A. Nfilla Cancer chemotherapy and Raynaud's phenomenon Ann Intern Med 98 1983 258 (letter)
117. P.R. Dunlop, P.M. Handy Raynaud's phenomenon and cryoglobulinemia during chemotherapy for testicular cancer Cancer Treat Rep 67 1983 317 318 (letter)
118. M.B. Garnick, G.P. Canellos, J.P. Richie Treatment and surgical staging of testicular and primary extragonadal germ cell cancer JAMA 250 1983 1733 1741
119. Lj. Kukla, D. Burrows, L. Bressler Bleomycin-induced Raynaud's phenomenon Arch Dermatol 117 1981 604 (letter)
120. B. Bostrom, W.G. Woods, N.K.L. Ramsay Cisplatin, vinblastine, and bleomycin (CVP) therapy for relapsed disseminated neuroblastoma Cancer Treat Rep 68 1984 1157 1158
121. S.D. Fossa, N. Aass, O. Kaalhus Long term survival and morbidity in patients with metastatic malignant germ cell tumors treated with cisplatin-based combination chemotherapy Cancer 58 1986 2600 2605
122. T. Stefenelli, R. Kuzmits, W. Ulrich Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer Eur Heart J 9 1988 552 556
123. S.W. Hansen, N. Olsen Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer Measurement of vasoconstrictor response to cold J Clin Oncol 7 1989 940 942
124. M. Boyer, D. Raghaven Intensive late toxicity assessment program for patients treated for metastatic germ cell tumors with cisplatin-containing combination chemotherapy Proc Am Soc Clin Oncol 8 1989 142 (abstr 552)
125. B.J. Roth, A. Greist, P.S. Kubilis Cisplatin-based combination chemotherapy for disseminated germ cell tumors Long-term follow-up J Clin Oncol 6 1988 1239 1247
126. G. Stoter, A. Koopman, C.P.J. Vendrick Ten-year survival and later sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin J Clin Oncol 7 1989 1099 1104
127. M. Brada, A. Horwich, M.J. Peckham Treatment of favorable-prognosis non- seminomatous testicular germ cell tumors with etoposide, cisplatin, and reduced dose of bleomycin Cancer Treat Rep 71 1987 655 656
128. I.S. Cohen, M.B. Mosher, E.J. O'Keefe Cutaneous toxicity of bleomycin therapy Arch Dermatol 107 1973 553 555
129. C.F. Von Gunten, E.L. Roth, J.H.V. Von Roenn Raynaud's phenomenon in three patients with acquired immune deficiency syndrome-related Kaposi sarcoma treated with bleomycin Cancer 72 1993 2004 2006
130. L. Flomaa, M. Pajunen, P. Virkkunen Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapy Acta Med Scand 216 1984 323 326
131. R.J. Fertakos, D.M. Mintzer Digital gangrene following chemotherapy for AIDS-related Kaposi's sarcoma Am J Med 93 1992 581 582
132. T.J.H.I. Reid, F.A. Lombardo, J. Redmond III Digital vasculitis associated with interferon therapy Am J Med 92 1992 702 703
133. A. Creutzig, L. Caspary, M. Freund The Raynaud's phenomenon and interferon therapy Ann Intern Med 125 1996 423 (letter)
134. C. Bachrneyer, D. Farge, E. Gluckman Raynaud's phenomenon and digital necrosis induced by interferon-alpha Br J Dermatol 135 1996 481 483
135. D. Linden Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis Lancet 352 1998 878 879 (letter)
136. E. Goffin, R. Angangio, L.M. Shapiro Digital gangrene following chemotherapy Am J Med 96 1994 571 (letter)
137. J.P.A. van Basten, H.J. Hoekstra, M.F. van Driel Sexual dysfunction in non-seminoma testicular cancer patients is related to chemotherapy-induced angiopathy J Clin Oncol 15 1997 2442 2448
138. C. Bokemeyer, C.C. Berger, M. Kuczyk Evaluation of long-term toxicity after chemotherapy for testicular cancer J Clin Oncol 14 1996 2923 2932
139. M. Raiser, C. Burns, P. Hartmann Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma Eur J Clin Microbiol Infect Dis 117 1998 58 60
140. M. Hladunewich, C. Sawka, A. Fam Raynaud's phenomenon and digital gangrene as a consequence of treatment for Kaposi's sarcoma J Rheumatol 12 1997 2371 2375
141. R. Malamet, R.A. Wise, W.H. Ettinger Nifedipine in the treatment of Raynaud's phenomenon Evidence for inhibition of platelet activation Am J Med 78 1985 602 608
142. R.J. Rodenheffer, J.A. Runner, F. Wigley Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon N Eng J Med 308 1983 880 883
143. A. Hantel, E.K. Rowinsky, R.C. Donehower Nifedipine and oncologic Raynaud's phenomenon Ann Intern Med 108 1988 767 (letter)
144. E.M. Mandel, U. Lewinski, M. Djaidetti Vincristine-induced myocardial infarction Cancer 30 1975 1979 1982
145. G. Somers, M. Abram, M. Witter Myocardial infarction A complication of vincristine treatment? Lancet 2 1976 690 (letter)
146. J.L. Lejonc, J.P. Vernant, I. Macquin Myocardial infarction following vinblastine treatment Lancet 2 1980 692 (letter)
147. J.P. Schuster, S.E. Jones Myocardial infarction in a 27 year old woman Possible complication of treatment with VP-16-213 (NSC-141540), mediastinal irradiation, or both Cancer Chemother Rep 59 1975 887 888 (letter)
148. J. Aisner, D.A. Van Echo, M. Whitaker A phase I trial of continuous infusion VP-16-213 (etoposide) Cancer Chemother Pharmacol 7 1982 157 160
149. J.E. Mortimer, L. Crowley, H. Eyre A phase II randomized study comparing sequential and combined intra-arterial cisplatin and radiation therapy for primary brain tumors Cancer 69 1992 1220 1793
150. J.A. Ricci, L. Goldstein Coronary artery disease in the presence of bleomycin therapy Cancer Treat Rep 66 1982 410 (letter)
151. N.J. Vogelzang, D.H. Frenning, B.J. Kennedy Coronary artery disease after treatment with bleomycin and vinblastine Cancer Treat Rep 53 1980 1159 1160 (letter)
152. N.J. Vogelzang, J.L. Torkelson, B.J. Kennedy Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin Cancer 56 1985 2765 2770
153. B.L. Samuels, N.J. Vogelzang, B.J. Kennedy Severe vascular toxicity associated with vinblastine, bleomycin and cisplatin chemotherapy Cancer Chemother Pharmacol 19 1987 253 256
154. D.C. Bodensteiner Fatal coronary artery fibrosis after treatment with bleomycin, vinblastine, and cisplatin South Med J 74 1981 898 899
155. D.C. Doll, A.F. List, F.A. Greco Acute arterial ischemic events following cisplatin-based combination chemotherapy for germ cell tumors of the testis Ann Intern Med 105 1986 48 51
156. J.A. Talcott, T.S. Herman Acute ischemic vascular events and cisplatin Ann Intern Med 107 1987 121 197 (letter)
157. F. Icli, H. Karaoguz, D. Dincol Severe vascular toxicity associated with cisplatin-based chemotherapy Cancer 72 1993 587 593
158. K.W. House, S.R. Simon, R.P. Pugh Chemotherapy-induced myocardial infarction in a young man with Hodgkin's disease Clin Cardiol 15 1992 122 125
159. M.L. Rothenberg, N.J. Meropol, E.A. Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin Summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
160. J.F. Boiven, G.B. Hutchinson, J.H. Lubin Coronary artery disease mortality in patients treated for Hodgkin's disease Cancer 69 1992 1241 1247
161. C.R. Nichols, B.J. Roth, S.D. Williams No evidence of acute cardiovascular complications of chemotherapy for testicular cancer An analysis of the Testicular Cancer Intergroup Study J Clin Oncol 10 1992 760 765
162. R.S. Yancey, M. Talpaz Vindesine-associated angina and ECG changes Cancer Treat Rep 66 1982 587 588 (letter)
163. F. Dexeus, C.J. Logothetis, M.L. Samuels Continuous infusion of vinblastine for advanced hormone refractory prostate cancer Cancer Treat Rep 69 1985 885 886
164. M. Subar, F.M. Muggia Apparent myocardial ischemia associated with vinblastine administration Cancer Treat Rep 70 1986 690 691 (letter)
165. M. Tomirotti, R. Riundi, S. Pulici Ischemic cardiopathy from cis-diamminedichloroplatinum (CDDP) Tumori 70 1984 235 236
166. L. Shachor, B. Beker, Y. Geffen Acute ECG change during cyclophosphamide infusion in a patient with bronchogenic carcinoma Cancer Treat Rep 69 1985 734 735 (letter)
167. D.A. White, L.S. Schwartzberg, M.G. Kris Acute chest pain syndrome during bleomycin infusions Cancer 59 1987 1582 1585
168. S. Yano, K. Shimada Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer Jpn Circ J 60 1996 185 188
169. L. Rodriguez, J. Collazos, M. Gallardo Angina pectoris following cisplatin, etoposide, and bleomycin in a patient with advanced testicular cancer Ann Pharmacother 29 1995 138 139
170. B. Leone, M. Rabinovitch, C.R. Ferrari Cardiotoxicity as a result of 5-fluorouracil therapy Tumori 71 1985 55 57
171. S. Sanani, M. Spaulding, A.R. Masud 5-FU cardiotoxicity Cancer Treat Rep 65 1981 1123 1125
172. R. Labianca, G. Beretta, M. Clerici Cardiotoxicity of 5-fluorouracil A study of 1083 patients Tumori 68 1982 505 510
173. A. Pottage, S. Holt, S. Ludgate, A.O. Langlands Fluorouracil cardiotoxicity Br Med J 1 1978 547
174. N. Freeman, M. Costanza 5-Fluorouracil associated cardiotoxicity Cancer 61 1988 36 45
175. W. Gradishar, E. Vokes, R. Schilsky Vascular events in patients receiving high-dose infusional 5-fluorouracil based chemotherapy The University of Chicago experience Med Pediatr Oncol 19 1991 8 15
176. D.A. Vorbiof Cardiotoxicity of 5-fluorouracil South Afr Med J 61 1982 635 637
177. R.G. Dent, L. McColl 5-Fluorouracil and angina Lancet 1 1975 347 348 (letter)
178. D.L. Stevenson, D.P. Mikhaikidis, D.S. Gillet Cardiotoxicity of 5-fluorouracil Lancet 2 1977 406 407 (letter)
179. M. Soukop, J.G. MeVie, K.C. Cahnan 5-Fluorouracil cardiotoxicity Br Med J 1 1978 14 22
180. N.A. Kleiman, D.E. Lehane, E. Geyer Prinzmetal's angina during 5-fluorouracil chemotherapy Am J Med 82 1987 566 568
181. T. Gauci, G. Zampa Cardiotoxicity of 5-FU Tumori 65 1979 487 495
182. T. Umsawasdi, P. Sawamkatata Cardiotoxicity of 5-fluorouracil Cancer Chemother Rep 59 1975 1051 1053
183. L. Oleksowicz, H.W. Bruckner Prophylaxis of 5-fluorouracil-induced coronary vasospasm with calcium channel blockers Am J Med 85 1988 750 751
184. S. Chaudary, S.Y.K. Song, B.E. Jaski Profound, yet reversible, heart failure secondary to 5-fluorouracil Am J Med 85 1988 454 456
185. C. Collins, P.L. Weiden Cardiotoxicity of 5-fluorouracil Cancer Treat Rep 71 1987 733 736
186. S. Rezkalla, R.A. Kloner, J. Ensley Continuous ambulatory ECG monitoring during fluorouracil therapy A prospective study J Clin Oncol 7 1989 509 514
187. B. Patel, R.A. Kloner, J. Ensley 5-Fluorouracil cardiotoxicity Left ventricular dysfunction and effects of coronary dilators Am J Med Sci 294 1987 238 243
188. A.A. Jakubowski, N. Kemeny Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil Cancer 62 1988 266 269
189. N.C. Robben, A.W. Pippas, J.O. Moore The syndrome of 5-fluorouracil cardiotoxicity an elusive cardiomyopathy Cancer 71 1993 493 509
190. C. Schooben, E. Papageorgiou, A. Harstick Cardiotoxicity of 5-fluorouracil in combination with foiling acid in patients with gastrointestinal cancer Cancer 72 1993 2242 2247
191. M. De Fond, M.C. Makt-Martino, P. Jaillais Cardiotoxicity of high dose continuous infusion fluorouracil A prospective clinical study J Clin Oncol 10 1992 1795 1801
192. N.M. Anderson, J.J. Lokich, C. Moore The syndrome of 5-fluorouracil cardiotoxicity an elusive cardiomyopathy Cancer 72 1993 9787-2288
193. A.A. Forastiere, B. Metch, D.E. Schuller Comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck A Southwest Oncology Group Study J Clin Oncol 10 1992 1245 1251
194. M.W. Saif, E. Szabo, J. Grem The clinical syndrome of 5-fluorouracil cardiotoxicity Proc Am Soc Clin Oncol 20 2001 404a (abstr 1613)
195. J.F. Pizzolato, M. Baum, R.M. Steingart Cardiac toxicity of 5FU does prophylactic telemetry monitoring of patients at increased risk for cardiac toxicity improve safety? A 10-year experience Proc Am Soc Clin Oncol 22 2004 755s (abstr)
196. M.T. Meinardi, J.A. Gietema, W.T.A. van der Graaf Cardiovascular morbidity in long term survivors of metastatic testicular cancer J Clin Oncol 18 2000 1725 1732
197. R.A. Huddart, A. Norman, M. Shahidi Cardiovascular disease as a long-term complication of treatment for testicular cancer J Clin Oncol 21 2003 1513 1523
198. A.J. Murgo Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents Semin Hematol 24 1987 161 177
199. S.C. Gulati, P. Sordiu, S. Kernpin Microangiopathic hemolytic anemia observed after treatment of epidermoid carcinoma with mitomycin C and 5-fluorouraril Cancer 45 1980 2252 2257
200. W.T. Hanna, S. Krauss, R.F. Regester Renal disease after mitomycin C therapy Cancer 48 1981 2583 2588
201. E. Harden, V.S. Lucas, A. Proia Hemolytic uremic syndrome during therapy with mitomycin C (MMC) plus 5-fluorouracil (5-FU) Proc Am Soc Clin Oncol 1 1982 93 (abstr C-360)
202. M.K. Home III, B. Cooper Microangiopathic hemolytic anemia with metastatic adenocarcinonia Response to chemotherapy South Med J 75 1982 503 504
203. B.G. Jones, C.E. Newman, J.W. Fielding Intravascular hemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil
204. D.A. Karlin, J.R. Stroehlein Rash, nephritis, hypertension, and hemolysis in patients on 5-fluorouracil, doxorubicin, and mitomycin C Lancet 2 1980 534 535 (letter)
205. S. Krauss, T. Sonoda, A. Solomon Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C Cancer 1974 1598 1603
206. B.R. Kressel, K.P. Ryan, A.T. Kuong Microangiopathic hemolytic anemia, thrombocytopenia, and renal failure in patients treated for adenocarcinoma Cancer 48 1981 1734 1745
207. D.L. Laffay, R.R. Tubbs, R. Valenzuela Chronic glomerular microangiopathy and metastatic carcinoma Hum Pathol 10 1979 433 438
208. K.D. Lempert Hemolysis and renal impairment syndrome in patients on 5- fluorouracil and mitomycin C Lancet 2 1980 369 370 (letter)
209. M.E. Pavy, E.L. Wiley, M.D. Abeloff Hemolytic uremic syndrome associated with mitomycin therapy Cancer Treat Rep 66 1982 457 461
210. S.J. Rabadi, J.D. Khandekar, H.J. Miller Mitomycin-induced hemolytic uremic syndrome Case presentation and review of the literature Cancer Treat Rep 66 1982 1244 1247
211. K.W. Rump, J. Rieger, P.G. Landkisch Mitomycin-induced hemolysis and renal failure Lancet 2 1980 1037 1038 (letter)
212. U. Bruntsch, G. Froos, F. Tigges Microangiopathic hemolytic anemia, a frequent complication of mitomycin therapy in cancer patients Eur J Clin Oncol 20 1984 905 909
213. S. Zimmerman, F.F. Smith, T.M. Phillips Gastric carcinoma and thrombotic thrombocytopenic purpura Association with plasma immune complex concentration Br Med J 284 1982 1432 1434
214. D.J. Perry Reversible microangiopathic hemolytic anemia after mitomycin C Cancer Chemother Pharmacol 10 1983 223
215. N.W. Lyman, R. Michaelson, R.L. Viscuso Mitomycin-induced hemolytic uremic syndrome. Successful treatment with corticosteroids and intense plasma exchange Arch Intern Med 143 1983 1617 1618
216. J. Grocker, E.L. Jones Hemolytic-uremic syndrome complicating long-term mitomycin C and 5-fluorouracfl therapy for gastric carcinoma J Clin Pathol 36 1983 24 29
217. J.E. Cantrell Jr, T.M. Phillips, P.S. Schein Carcinoma-associated hemolytic-uremic syndrome A complication of mitomycin C chemotherapy J Clin Oncol 3 1985 723 734
218. J. Jolivet, L. Giroux, S. Laurin Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema A chemotherapy induced syndrome Cancer Treat Rep 67 1983 429 434
219. I.F. Tanriock Methotrexate and mitomycin for patients with metastatic transitional cell carcinoma of the urinary tract Cancer Treat Rep 61 1983 503 504
220. J.W.L. Fielding, S.L. Fagg, B.G. Jones An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer British Stomach Cancer Group World J Surg 7 1983 390 399
221. L. Laufnian, S. Courter, J. Iritchard Fatal mitomycin C (MMC) syndrome heralded by pulmonary symptoms Proc Am Soc Clin Oncol 2 1983 197 (abstr 768)
222. F.S. Ravikurnar, R. Sibley, K. Reed Renal toxicity of mitomycin C Am J Clin Oncol 7 1984 279 285
223. C.L. Loprinzi Mitomycin C-induced pulmonary and renal toxicities Wis Med J 83 1984 16 17
224. S. Ito, S. Hirono Two cases of microangiopathic hemolytic anemia caused by anticancer drugs which showed rapid improvement after administration of aspirin and dipyridamole Rinsho Ketsueki 23 1982 730 735
225. W. Jao, J.R. Manaligod Renal disease associated with mitomycin therapy Ultrastruct Pathol 5 1983 83 88
226. E. Boven, I.M. Findeo Mitomycin C. Interstitial pneumonitis and hemolytic uraemic syndrome Neth J Med 26 1983 153 156
227. A. Khojasteh, R.D. Reynolds, A.R. Garcia Hemolytic uremic-like syndrome following a single dose of mitomycin C Proc Am Soc Clin Oncol 3 1984 4 (abstr 16)
228. J.P. Van Speeuwel, M.H. Hemrika, C.E.M. Dammaat Letter to the editor Neth J Med 26 1983 287 288 (letter)
229. K.B. Peterson, W.E. Smith Mitomycin induced hemolytic uremic syndrome Samaritan Med 2 1984 17 20
230. P. Simon, J.P. Herve, M.P. Ramee La nephrotoxicite de la mitomycin C. Trois nouvelles observations et revue de la litterature Nephrologie 3 1982 152 157
231. G.R. Willie, S.M. Levy, R.E. Michaels Hemolytic uremic syndrome in a patient receiving mitomycin C and 5-fluorouracil Henry Ford Hosp Med J 31 1983 104 109
232. R. Valavaara, E. Nordman Renal complications of mitomycin C therapy with special references to the total dose Cancer 55 1985 47 50
233. V. Hug, A. Burgess, G. Blumenschein Effect of cyclophosphamide on the mitomycin-based syndrome of thrombotic thrombocytopenic purpura Cancer Treat Rep 69 1985 565 566 (letter)
234. T.M. Price, A.J. Murge, J.J. Keveney Renal failure and hemolytic anemia associated with mitomycin C A case report Cancer 55 1985 51 56
235. J. Verwey, E. Boven, J. Van Der Muelen Recovery from mitomycin C induced hemolytic uremic syndrome A case report Cancer 54 1984 2878 2881
236. G. Garibotto, N. Acquarone, S. Saffloti Successful treatment of mitomycin-C associated hemolytic uremic syndrome by plasmapheresis Nephron 51 1989 409 412
237. S.M. Fields, C.M. Lindley Thrombotic n-microangiopathy associated with chemotherapy A case report and review of the literature DICP 23 1989 582 588
238. R. Sheldon, D. Slaughter A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma Cancer 58 1986 1428 1436
239. A.L. Hostetter, R.R. Tubbs, T. Ziegler Chronic glomerular microangiopathy complicating metastatic carcinoma Hum Pathol 18 1987 342 348
240. J. Verwey, J.D. Vries, H.M. Pinedo Mitomycin C induced renal toxicity, a dose dependent side effect? Eur J Cancer Clin Oncol 23 1987 195 199
241. H.G. Mergenthaler, T. Binsack, W. Wilmanns Carcinoma associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-Adriamycin- mitomycin C combination chemotherapy Oncology 45 1988 11 14
242. J.T. McCarthy, B.A. Staats Pulmonary hypertension, hemolytic anemia, and renal failure A mitomycin associated syndrome Chest 89 1986 608 611
243. J.B. Lessesne, N. Rothschild, B. Erickson Cancer associated hemolytic uremic syndrome Analysis of 85 cases from a national registry J Clin Oncol 7 1989 781 789
244. K.M. Liu, A. Mittelman, E.E. Sproul Renal toxicity in man treated with mitomycin C Cancer 28 1971 1314 1320
245. R.B. Weiss, D.S. Poster The renal toxicity of cancer chemotherapeutic agents Cancer Treat Rev 9 1982 37 56
246. R.W. Haur, R. Verani, E.J. Weirunan Mitomycin associated renal failure. Case report and review Arch Intern Med 143 1983 803 807
247. L. Morel-Maroger Nephrology forum Adult hemolytic uremic syndrome Kidney Int 18 1980 125 134
248. G. Agnelli, P. Gresele, G.G. Nenci Clotting activation after blood transfusion in patients receiving 5-fluorouracil and mitomycin C treatment Cancer Chemother Pharmacol 5 1981 205 206 (letter)
249. S. Chow, J. Roscoe, D.C. Cattran Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome to mitomycin Am J Kidney Dis 7 1986 407 412
250. J.L. Grem, J.A. Merritt, P.P. Carbone Treatment of mitomycin associated microangiopathic hemolytic anemia with vincristine Arch Intern Med 46 1986 566 568
251. S.E. Zimmerman, F.F. Smith, T.M. Phillips Gastric carcinoma and thrombotic thrombocytopenic purpura Association with plasma immune complex concentrations Br Med J 284 1982 1432 1434
252. Korec, P.S. Schein, F.P. Smith Treatment of cancer associated hemolytic uremic syndrome with staphylococcal protein A immunoperfusion 5 J Clin Oncol 4 1986 210 215
253. H.W. Snyder Jr, A. Mittleman, A. Oral Treatment of cancer chemotherapy associated thrombocytopenia purpura/hemolytic uremic syndrome by protein A immunoadsorption of plasma Cancer 71 1993 1882 1892
254. J. Licciardello, J. Moake, C. Rudy Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy Oncology 42 1985 296 300
255. A.M. Jackson, B.D. Rose, L.G. Graff Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy Ann Intern Med 101 1984 41 44
256. B. Desablens, P. Fievet, A. Pruna Hemolytic-uremic syndrome after cancer chemotherapy without mitomycin C Nephron 42 1986 340 344
257. J. Van De Meer, E.G.E. De Vries, R. Vriesendorp Hemolytic uremic syndrome in a patient on cisplatin, vinblastine, and bleomycin J Cancer Res Clin Oncol 110 1985 119 122
258. W.J. Gradishar, E.E. Vokes, K. Mi Chemotherapy related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report Cancer 66 1990 1914 1918
259. P.R. Watson, T.H. Guthrie Jr, R.J. Caruana Cisplatin-associated hemolytic uremic syndrome Successful treatment with staphylococcal protein A column Cancer 64 1989 1400 1403
260. A.S. Coates, A. Childs, K. Cox Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron Ann Oncol 3 1992 773 774
261. M. van der Heijden, S.P. Ackland, S. Deveridge Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy A case report and review of the literature Acta Oncol 37 1998 107 109
262. R.W. Walker, M.K. Rosenblum, S.J. Kempin Carboplatin-associated thrombotic microangiopathic hemolytic anemia Cancer 64 1989 1017 1020
263. Case records MGH. Case 16-1988 N Engl J Med 318 1988 1047 1057
264. R.W. Carey, N. Harris Thrombotic microangiopathy in three patients with cured lymphoma Cancer 63 1989 1393 1397
265. J.J. Byrnes, H. Baquerizo, M. Gonzalez Thrombotic thrombocytopenic purpura subsequent to acute myelogenous chemotherapy Am J Hematol 21 1986 299 304
266. J.W. Leach, T. Pham, D. Diamandidis Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome following treatment with deoxyforcomycin in a patient with cutaneous T-cell lymphoma A case report Am J Hem 61 1999 268 270
267. M.C. Fung, A.M. Storniolo, B. Nguyen A review of hemolytic uremic syndrome in patients with gemcitabine therapy Cancer 85 1999 2023 2032
268. D.C.H. Harris, S. Lawrence, K.F. Bradstock Intraglomerular thrombosis with deoxycoformycin-reversible acute renal failure Clin Nephrol 21 1984 194 196
269. C. Sakai, T. Takagi, S. Wakatsuki Hemolytic uremic syndrome due to deoxycoformycin A report of the second case Intern Med 34 1995 593 596
270. K. Honda, A. Ando, M. Endo Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia Am J Kidney Dis 30 1997 123 130
271. D.C. Fisher, G.B. Sherrill, A. Hussein Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer Bone Marrow Transplant 18 1996 193 198
272. A.R. Pettitt, R.E. Clark Thrombotic microangiopathy following bone marrow transplantation Bone Marrow Transplant 14 1994 495 504
273. J.L. Moake, J.J. Byrnes Thrombotic microangiopathies associated with drugs and bone marrow transplantation Hematol Oncol Clin North Am 10 1996 485 497
274. S.N. Rabinowe, R.J. Soiffer, N.J. Tarbell Hemolytic uremic syndrome following bone marrow transplantation in adults for hematologic malignancies Blood 77 1991 1837 1844
275. R. Fuge, J.M. Bird, A. Fraser The Clinical features, risk factors and outcome of thrombotic thrombocytopenia purpura occurring after bone marrow transplantation Br J Haematol 113 2001 59 64
276. H.V. Ojik, D.H. Biesma, R. Fijhnheer Cyclosporin for thrombotic thrombocytopenic purpura after autologous bone marrow transplantation Br J Haematol 96 1997 641 643
277. G.H. Sack, J. Levin, W.R. Bell rousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms Clinical, pathophysiologic and therapeutic features Medicine 56 1997 1 37
278. L.J. Kukla, W.P. McGuire, T. Lad Acute vascular episode associated with therapy for carcinoma of the upper aerodigestive tract with bleomycin, vincristine, and cisplatin Cancer Treat Rep 66 1982 369 370
279. B. Fallon, J. Clark, E. Frei Vascular complications during cisplatin-bleomycin-methotrexate and cisplatin 5-FU in induction chemotherapy for advanced stage III and IV squamous cell carcinoma of the head and neck Proc Am Soc Clin Oncol 5 1986 134 (abstr 521)
280. R. Allerton Acute mesenteric ischemia associated with 5-FU, cisplatin and vincristine chemotherapy Clin Oncol 8 1996 116 117
281. B.M.J. Cantwell, K.A. Manniz, J.T. Roberts Thromboembolic events during combination chemotherapy for germ cell malignancy Lancet 2 1988 1086 1087 (letter)
282. M.R. Hall, M.A. Richards, P.G. Harper Thromboembolic events during combination chemotherapy for germ cell malignancy Lancet 2 1986 1259 (letter)
283. G.S. Lederman, M.B. Garnick Pulmonary emboli as a complication of germ cell cancer treatment J Urol 137 1987 1236 1237
284. P.M. Czaykowski, M. Moore, I.F. Tannock High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy J Urol 160 1998 2021 2024
285. I.W.H. Garsft, G.G. Cooper, J.M. Hood Arterial thrombosis after treatment with bleomycin and cisplatin Br Med J 300 1990 10 18 (letter)
286. R.G. Molloy, G.C. Welch, J.K. Drury Arterial thrombosis after chemotherapy with cisplatin, vinblastine and methotrexate Br J Clin Pract 49 1995 50 51
287. G. Lepidini, F. Biancari, V. D'Andma Severe thrombosis after chemotherapy for metastatic adenocarcinorna of the testis maintaining complete remission for a long period Scand J Urol Nephrol 31 1996 221 299
288. E.J. Seiffer, R.C. Young, D.L. Longo Deep venous thrombosis during therapy for Hodgkin's disease Cancer Treat Rep 69 1985 1011 1013
289. C.S. Clarke, B.W. Otridge, D.N. Carney Thromboembolism. A complication of weekly chemotherapy in the treatment of non-Hodgkin's lymphoma Cancer 66 1990 2027 2030
290. B.M.J. Cantwell, J. Carmichael, S.E. Ghani Thromboses and thrombolic in patients with lymphoma during cytotoxic chemotherapy Br Med J 2 1988 179 180
291. T.P. Miller, S. Dahlberg, J.K. Weich Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM A groupwide Southwest Oncology Group Study J Clin Oncol 8 1990 1951 1958
292. R.B. Weiss, D.C. Tormey, J.F. Holland Venous thrombosis during multimodality treatment of primary breast carcinoma Cancer Treat Rep 65 1981 677 679
293. B.W. Booth, R.B. Weiss Venous thrombosis during adjuvant chemotherapy N Engl J Med 305 1981 168 (letter)
294. A. Manni, J.E. Trujillo, O.H. Pearson Sequential use of endocrine therapy and chemotherapy for metastatic breast cancer Effects on survival Cancer Treat Rep 64 1980 111 116
295. L.T. Goodnough, H. Saito, A. Manni Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients Cancer 54 1984 1264 1268
296. M.N. Levine, M. Gent, J. Hirsh The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer N Eng J Med 318 1988 404 407
297. T. Saphner, D.C. Toriney, R. Gray Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer J Clin Oncol 9 1991 286 294
298. B. Fisher, C. Redmond, D.L. Wickerham Doxorubicin-containing regimens for the treatment of stage II breast cancer The National Surgical Adjuvant Breast and Bowel Project experience J Clin Oncol 7 1989 572 582
299. K.I. Pritchard, L. Pater, N. Paul Thromboembolic complications related to chemotherapy in a National Institute of Canada randomized trial for tamoxifen versus tamoxifen plus chemotherapy in postmenopausal women with axillary node positive receptor positive breast cancer Proc Am Soc Clin Oncol 8 1989 25 (abstr 92)
300. J.G. Wall, R.B. Weiss, L. Norton Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma A Cancer and Leukemia Group B study Am J Med 87 1989 1455 1466
301. S.E. Rivkin, S. Green, B. Metch Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients A Southwest Oncology Group Study J Clin Oncol 12 1994 2078 2085
302. C. Theodossiou, G. Kroog, S. Ettinghausen Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3 Cancer 74 1994 2808 2810
303. P.C. Clahsen, C.J.H. van De Velde, J.P. Julien Thromboembolic complications after perioperative chemotherapy in women with early breast cancer A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study J Clin Oncol 12 1994 1266 1271
304. M. Levine, J. Hirsh, M. Gent Double-blind randomized trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer Lancet 343 1994 886 889
305. K.I. Pritchard, A.H.G. Paterson, N.A. Paul Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant chemotherapy for women with breast cancer J Clin Oncol 14 1996 2731 2737
306. A.A. Shlebak, D.B. Smith Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and or hormonal therapy Cancer Chemother Pharmacol 39 1997 462 466
307. A.T.C. Chan, W. Yeo, W.T. Leung Thrombolic events with paclitaxel Clin Oncol 8 1996 133 (letter)
308. N. Deshmukh, S.P. Tripathi Thrombosis of tibial arteries in a patient receiving tamoxifen therapy Cancer 76 1995 1006 1008
309. I.C. Weitz, V.K. Israel, H.A. Liebman Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden Cancer 79 1997 2024 2027
310. M.R. Hall, M.A. Richards, P.G. Harper Thromboembolic events during combination chemotherapy for germ cell malignancy Lancet 2 1988 1259 (letter)
311. N.I. Weijl, M.F.J. Rutten, A.H. Zwinderman Thromboembolic events during chemotherapy for germ cell cancer A cohort study and review of the literature J Clin Oncol 18 2000 2169 2178
312. T.J. Lynch Jr, F. Kass, L.A. Kalish Cisplatin, 5-fluorouracil, and etoposide for advanced non-small lung cancer Cancer 71 1993 2953 2957
313. J. Mathews, R. Goel, W.K. Evans Arterial occlusion in patients with peripheral vascular disease treated with platinum-based regimens for lung cancer Cancer Chemother Pharmacol 40 1997 19 22
314. B.S. Kasimis, A.S.D. Spiers Thrombotic complications in patients with advanced prostatic cancer treated with chemotherapy Lancet 1 1979 159 (letter)
315. P.F. Del Prado, J.A. Meana, J.R. Carrion Acute cerebrovascular accident after treatment with cisplatin Acta Oncol 31 1992 593 595
316. D. Gandia, M. Spielman, J. Kac Cerebrovascular accident associated with chemotherapy for oesophageal carcinoma Eur J Cancer 28 1992 245
317. P. Sevelda, K. Mayerhofer, A. Obermain Thrombosis with paclitaxel Lancet 343 1994 727 (letter)
318. J.C. Becker, B. Winkler, S. Klingert Antiphospholipid syndrome associated with immunotherapy for patients with melanoma Cancer 73 1994 1621 1624
319. J.A. Conti, M. Scher Acute arterial thrombosis after escalated-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy with recombinant granulocyte colony-stimulating factor Cancer 70 1992 2699 2702
320. K.S. Antman, J.D. Griffin, A. Elias Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression N Engl J Med 319 1988 593 598
321. L.C. Stephens, W.D. Haire, K.S. Pokorny Granulocyte macrophage colony stimulating factor High incidence of apheresis catheter thrombosis during stem cell collection Bone Marrow Transplant 11 1993 57 59
322. Y. Kawachi, A. Watanabe, T. Uchida Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony stimulating factor Br J Haematol 94 1996 413 416
323. W.M. Stadler, N.J. Vogelzang, R. Amato Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cell cancer A University of Chicago phase II consortium study J Clin Oncol 18 2000 371 375
324. M. Zangari, E. Siegel, B. Barlogie Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide Implications of therapy Blood 100 2002 1168 1171
325. M. Zangari Thalidomide and thromboembolism Blood 99 2002 4249 (letter)
326. M. Steurer, I. Sudmeier, R. Stauder Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with Darbepoietin-alpha Br J Haematol 121 2003 101 103
327. A.A. Desai, N.J. Vogelzang, B.I. Rini A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma Cancer 95 2002 1629 1636
328. B. Fisher, J. Costantino, C. Redmond A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors N Engl J Med 320 1989 479 484
329. M. Cushman, J.P. Costantino, E.G. Bovill Effect of tamoxifen on venous thrombosis risk factors in women without cancer The Breast Cancer Prevention Trial Br J Haematol 120 2003 109 116
330. L.E. Rutqvist, A. Mattsson Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockhohn Breast Cancer Study Group J Natl Cancer Inst 85 1993 1398 1406
331. B.F. Issell, S.T. Crooke Etoposide (VP-16-213) Cancer Treat Rev 6 1979 107 124
332. P.J. O'Dwyer, M.T. Alonso, B. Leyland-Jones Teniposide A review of 12 years of experience Cancer Treat Rep 68 1984 1455 1466
333. K.H. Antman, R.J. Mayer, E. Frei Vascular, hormonal, teratogenic and miscellaneous toxicities of chemotherapeutic agents M.C. Perry T.W. Yarbro Toxicity of Chemotherapy 1984 Grune & Stratton Philadelphia, PA 521 538
334. J.M. Buesa, M. Garcia, M. Vaile Phase I trial of intermittent high-dose dacarbazine Cancer Treat Rep 68 1984 499 504
335. W.D. Henner, W.P. Peters, J.P. Eder Pharmacokinetics and immediate effects of high-dose carmustine in man Cancer Treat Rep 70 1986 877 880
336. S.S. Legha, M. Keating, S. Picket Phase I clinical investigation of homoharringtonine Cancer Treat Rep 68 1984 1085 1091
337. J.A. Neidhart, D.C. Young, D. Derocher Phase I trial of homoharringtonine Cancer Treat Rep 67 1983 801 804
338. R.P. Warnell Jr, C.J. Coonley, T.S. Gee Homoharringtonine An effective new drug for remission induction in refractory non-lymphoblastic leukemia J Clin Oncol 3 1985 617 621
339. S.M. Carndchael, L. Eagieton, C.R. Ayers Orthostatic hypotension during vincristine therapy Arch Intern Med 126 1970 290 293
340. N.J. DiBella Vincristine-induced orthostatic hypotension A prospective clinical study Cancer Treat Rep 64 1980 359 360 (letter)
341. M. Kletzel, N. Jaffe Systemic hypertension A complication of intra-arterial cis-diammine dichloroplatinum (II) infusion Cancer 47 1981 245 247
342. R.M. Harrell, R. Sibley, N.J. Vogelzang Renal vascular lesion after chemotherapy with vinblastine, bleomycin, and cisplatin Am J Med 73 1982 429 433
343. S.W. Hansen, S. Growth, G. Augured Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer J Clin Oncol 6 1988 1728 1731
344. S.D. Spinach Procarbazine Ann Intern Med 81 1974 795 800
345. P.I. O'Dwyer, R.B. Weiss Hypersensitivity reactions induced by etoposide Cancer Treat Rep 68 1984 959 961
346. R.B. Weiss Hypersensitivity reactions to cancer chemotherapy M.C. Perry J.W. Yarbro Toxicity of Chemotherapy 1984 Grune & Stratton Philadelphia, PA 101 123
347. B.C. Kuenen, L.R. Egdbert, E.F. Smit Dose finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors J Clin Oncol 20 2002 1657 1667
348. K.K. Kampmann, T. Graves, S.D. Rogers Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions Cancer 63 1989 2482 2485
349. W.C. Burgdorf, W.A. Gilmore, R.G. Canick Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia Ann Intern Med 97 1982 61 62
350. M.R. Baer, L.E. King, S.N. Wolff Palmer-plantar erythrodysesthesia and cytarabine Ann Intern Med 102 1985 556 (letter)
351. C. Comonnier, J.C. Roujeau, J.P. Vernant Cancer chemotherapy and acral erythema Ann Intern Med 97 1982 785 (letter)
352. F.S. Silver, L.R. Espinoza, R.C. Hartmann Acral erythema and hydroxyurea Ann Intern Med 98 1983 675 (letter)
353. J.J. Lokich, C. Moore Chemotherapy-associated palmer-plantar erythrodysesthesia syndrome Ann Intern Med 101 1984 798 799
354. L.D. Feldman, J.A. Ajani Fluorouracil-associated dermatitis of the hands and feet JAMA 254 1985 34 79
355. C.F. Curtan, J.F. Luce Fluorouracil and palmar-plantar erythrodysesthesia Ann Intern Med 111 1989 858 (letter)
356. S.J. Vukelja, F.A. Lanbando, W.D. James Pyridoxine for the palmar-plantar erythrodysesthesia syndrome Ann Intern Med 111 1989 688 689 (letter)
357. J. Bellmunt, M. Mavarno, R. Hidalgo Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil Tumori 74 1988 329 331
358. S. Chiara, M.T. Nobile, C. Barzacchi Hand-foot syndrome induced by high dose, short-term, continuous 5-tluorouracil infusion Eur J Cancer 33 1997 967 969
359. A. Lurlo, M. Fornier, S. Caldiera Palmar-plantar erythrodysaesthesia syndrome due to 5-fluorouracil therapy - An underestimated toxic event? Acta Oncol 36 1997 653 654
360. L.A. Doyle, C. Berg, G. Bottino Erythema and desquamation after high-dose methotrexate Ann Intern Med 98 1983 611 612
361. G.J. Cox, D.B. Robertson Toxic erythema of palms and soles associated with high dose mercaptopurine chemotherapy Arch Dermatol 199 1986 1413 1414
362. C.P. Murphy, E.A. Harden, R.H. Herzig Dose related cutaneous toxicities with etoposide Cancer 71 1993 153 155
363. C. Twelves, P. Harper, C.V. Cutsem A phase III trial of Xeloda (capecitabine) in previously untreated advanced metastatic colorectal cancer Proc Am Soc Clin Oncol 18 1999 263a (abstr 1010)
364. J.A. Conti, N.E. Kemeny, L.B. Saltz Irinotecan is an active agent in untreated patients with metastatic colorectal cancer J Clin Oncol 14 1996 709 715
365. P.M. Hoff, V. Valero, N. Ibrahim Hand-foot syndrome following prolonged infusion of high doses of vinorelbine Cancer 82 1998 965 969
366. D. Argila, J.D. Dominguez, L. Iglesias Taxol-induced acral erythema Dermatology 192 1996 377-37
367. G.C. Zimmerman, J.H. Keeling Prevention of docetaxel-induced erythrodysesthesia with local hypothermia J Natl Cancer Inst 86 1994 557 558
368. S. Vukelia, W.J. Baker, H.A. Burris Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere J Natl Cancer Inst 1993 1432 1433
369. J. Bastida, C. Diaz-Cascajo, S. Borghi Chemotherapy induced acral erythema due to tegafur Acta Dermatol Venereol 77 1997 72 73 (letter)
370. L.R. Buceta, G.F. Buezo, P.F. Penas Paimar plantar erythrodysaesthesia syndrome and other cutaneous side effects after treatment with tegafur Acta Dermatol Venereol 77 1997 80 81 (letter)
371. F.M. Muggia, J.D. Hainsworth, S. Jeffers Phase II study of liposomal doxorubicin in refractory ovarian cancer Antitumor activity and toxicity modification by liposomal encapsulation J Clin Oncol 15 1997 987 993
372. M.C. Burke, J.D. Bernhard, A.D. Michelson Chemotherapy induced painful acral erythema in childhood Burgdorf's reaction Am J Pediatr Hematol 11 1989 44 45
373. Z. Demircay, O. Gurbuz, T.B. Alpdogan Chemotherapy induced acral erythema in leukemic patients A report of 15 cases Int J Dermatol 36 1997 593 598
374. H. Ogawa, H. Sugiyama, Y. Tani High incidence of chemotherapy induced acral erythema in female patients with non-Hodgkin lymphoma treated with the VACOP-B regimen Leuk Lymphoma 29 1997 171 177
375. J.S. Patel Pyridoxine for hand-foot syndrome Pharmacy 34 1999 604 609
376. M. Lauman, J. Mortimer Effect of pyridoxine on the incidence of palmar plantar erythroderma in patients receiving capecitabine Proc Am Soc Clin Oncol 20 2001 392a (abstr 1565)
377. D. Pendharkar, H. Goyal Novel management of capecitabine induced hand foot syndrome Proc Am Soc Clin Oncol 22 2004 755s (abstr 8105)
378. E.C. Kingsley 5-Fluorouracil dermatitis prophylaxis with a nicotine patch Ann Intern Med 120 1994 8135 (letter)
379. L.E. Gibson Cutaneous vasculitis Approach to diagnosis and systemic associations Mayo Clin Proc 65 1990 791-229
380. S. Paydays, S. Zorludemir, B. Sahin Vasculitis and leukemia Leuk Lymphoma 40 2000 105 112
381. C.G. Fonderila, G.A. Milone, S. Parlovsky Cutaneous vasculitis after intermediate dose of methotrexate Br J Haematol 72 1989 591 592
382. M. Navarro, R. Pedragosa, A. Lafuerza Leukocytoclastic vasculitis after high dose methotrexate Ann Intern Med 105 1986 471 472 (letter)
383. C.R. Marks, R.F. Willkins, K.R. Wilske Small-vessel vasculitis and methotrexate Ann Intern Med 100 1984 916 (letter)
384. E.K. Rowinsky, W.O. McGuire, G.J. Anhalt Hexamethylene bisacetamide induced cutaneous vasculitis Cancer Treat Rep 71 1987 471 474
385. I. Ahmed, K.R. Chen, H. Nakayama Cytosine arabinoside induced vasculitis Mayo Clin Proc 73 1998 239 242
386. J.M. Denefrio, R.S. Kaplan, M.A. Eisenberger Phase II study of cyclophosphamide and cytarabine in the treatment of metastatic adenocarcinoma of the colon and rectum Cancer Treat Rep 65 1981 163 164
387. I.D. Bucaloiu, S. Dubagunta, K.K. Pachipala Fluorouracil related small bowel vasculitis J Clin Oncol 21 2003 2441 2442
388. A.A. Voorburg, F.T. van Beek, P.H. Slee Vasculitis due to gemcitabine Lung Cancer 37 2003 22 (letter)
389. Y. Suzuki, Y. Tokuda, Y. Saitu Combination of trastuzumab and vinorelbine in metastatic breast cancer Jpn J Clin Oncol 33 2003 524-517
390. S. Paydas, S. Yavuz, U. Disel Vasculitis associated with all trans retinoic acid in a case with acute promyelocytic leukemia Leuk Lymphoma 44 2003 547 548
391. J.C. Steinmetz, R. DeConti, R. Ginsburg Hypersensivity vasculitis associated with 2-deoxycoformycin and allopurinol therapy Am J Med 86 1989 499 (letter)
392. H.S. Greenberg, W.E. Ensminer, J.F. Seeger Intraarterial BCNU chemotherapy for the treatment of malignant gliomas of the central nervous system A preliminary report Cancer Treat Rep 65 1981 803 810
393. W.D. DeWys, E.D. Fowler Report of vasculitis and blindness after intra carotid injection of 1,3-bis (2-chloroethyl)-l-nitrosourea (BCNU: NSC-409962) in dogs Cancer Chemother Rep 57 1973 33 40
394. W. Bernauer, A. Gratwohl, A. Keller Microvasculopathy in the ocular fundus after bone marrow transplantation Ann Intern Med 116 1991 956 957
395. G. Wilding, R. Caruso, T.S. Lawrence Retinal toxicity after high-dose cisplatin therapy J Clin Oncol 3 1985 1683 1685
396. L.G. Feun, S. Wallace, D.J. Stewart Intracarotid infusion of cisdiamminedichloro-platinum in the treatment of recurrent malignant brain tumors Cancer 54 1984 794 799
397. E.M. Rankin, J.F. Pitts Ophthalmic toxicity during carboplatin therapy Ann Oncol 4 1993 337 338
398. K.A. Semb, S. Aamdal, P. Oan Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment J Clin Oncol 16 1998 3426 3432
399. R.N. Schwartz, L. Stover, J. Dutcher Managing toxicities of high-dose interleukin-2 Oncology 16 2002 11 20
400. K. Pulkkanen, V. Kataja, R. Johansson Systemic capillary syndrome resulting from gemcitabine treatment in renal cell carcinoma A case report J Chemo 15 2003 287 289
401. T. DePas, G. Curigliano, L. Franceschelli Gemcitabine induced capillary leak syndrome Ann Oncol 12 2001 1651 1652
402. E. Naubec, O. Oberlin, K. Belhadj Subcutaneous inflammatory edema induced by MINE chemotherapy Ann Dermatol 128 2001 534 537
403. J.S. Lazo Endothelial injury caused by antineoplastic agents Biochem Pharmacol 35 1986 1912 1923
404. G.L. Nicholson, S. Custead Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity Cancer Res 45 1985 331 336
405. I.Y.R. Adamson, D.H. Bowden The pathogenesis of bleomycin-induced pulmonary fibrosis in mice Am J Pathol 77 1974 185 198
406. K. Otsuka, S.L. Murota, Y. Mori Stimulatory effect of bleomycin on the hyaluronic acid synthetase in cultured fibroblasts Biochem Pharmacol 27 1978 1551 1554
407. W.F. Finch, G.P. Rodan, R.B. Buckingham Bleomycin-induced scleroderma J Rheumatol 7 1980 651 659
408. P.L. Mosekey, C. Heniken, G.W. Hunninghake Augmentation of fibroblast proliferation by bleomycin J Clin Invest 78 1986 1150 1154
409. V.E. Gould, J. Miller Sclerosing alveolitis induced by cyclophosphamide Ultrastructural observations on alveolar injury and repair Am J Pathol 81 1975 513 530
410. V. Cattell Mitomycin induced hemolytic uremic kidney An experimental model in the rat Am J Pathol 121 1985 88 95
411. D. Charba, J.L. Moake, N.I.A. Harris Abnormalities of von Willebrand factor multimers in drug-associated thrombotic microangiopathies Am J Hematol 42 1993 268 277
412. M. Furlan, R. Robles, M. Solenthaler Deficient activity of von Willebrand factor-cleaving protease in chrome relapsing thrombotic thrombocytopenic purpura Blood 89 1997 3097 4003
413. R.M. van der Plas, M.E. Sdiiphorst, E.G. Huizinga von Willebrand factor
414. A.C. Smith, M.R. Boyd Effects of BCNU on pulmonary and serum angiotensin converting enzyme activity in rats Biodiem Pharmacol 32 1983 3719 3722
415. J.S. Lazo Angiotensin converting enzyme activity in mice after subacute bleomycin administration Toxicol Appl Pharmacol 59 1981 395 404
416. A. Lerinan, F.L. Hildebrand Jr, K.B. Margulies Endothelin. A new cardiovascular regulatory peptide Mayo Clin Proc 65 1990 1441 1455
417. K. Kanno, Y. Hirata, T. Emori Endothelin and Raynaud's phenomenon Am J Med 90 1991 130 132
418. U. Gobble, W. Ebel, H. Jurgens Coagulation changes following bleomycin treatment in animals Proc Am Soc Clin Oncol 2 1983 39 (abstr 155)
419. T. Yen, J.D. Walsh, G. Pejler Cisplatin-induced platelet activation requires mononuclear cells Role of GMP-140 and modulation of procoagulant activity Br J Haematol 83 1993 259 269
420. T.J. Panella, W. Peters, J.G. White Platelets acquire a secretion defect after high dose chemotherapy Cancer 65 1990 1711 1716
421. M.A. Ruiz, I. Marugan, P. Estelles The influence of chemotherapy on the plasmatic coagulation and fibrinolytic system in lung cancer patients Thromb Haemost 158 1987 110 (abstr)
422. R.L. Edwards, M. Klaus, E. Matthews Heparin abolishes the chemotherapy induced increase in plasma fibrinopeptide A levels Am J Med 89 1990 25 28
423. T. Kuzel, B. Exparaz, D. Green Thrombogenity of intravenous 5-fluorouracil alone or in combination with cisplatin Cancer 65 1990 885 889
424. L. Canobbio, T. Passio, A. Ardizzoni Hypercoagulable state induced by cytostatic drugs in stage II breast cancer patients Cancer 54 1986 1032 1036
425. L. Conard, M.H. Horellou, P. Van Dreden Decrease in protein C in L-asparaginase-treated patients Br J Haematol 59 1985 725 727 (letter)
426. J.S. Rogers II, A.F. Murgo, J.A. Fantana Chemotherapy for breast cancer decreases plasma protein C and protein S J Clin Oncol 6 1988 276 281
427. S.E. Feffer, L.S. Carinosino, R.L. Fox Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil Cancer 63 1989 1303 1307
428. B.G. Gordon, W.D. Haire, D.F. Patton Thrombotic complications of BMT association with protein C deficiency Bone Marrow Transplant 11 1993 61 65
429. C. Rella, M. Coviello, F. Giotta A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy Breast Cancer Treat Res 40 1996 151 159
430. R.E. Enck, C.N. Rios Tamoxifen treatment of metastatic breast cancer and antithrombin III levels Cancer 53 1984 2607 2609
431. V.C. Jordan, N.F. Fritz, D.C. Tormey Long term adjuvant therapy with tamoxifen and effects on sex hormone binding globulin and antithrombin III Cancer Res 45 1987 4517 4519
432. A.L. Jones, T.J. Fowles, J.G. Trelearen Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women Br J Cancer 66 1992 744 747
433. R.R. Love, T.S. Surawicz, E.L. Williams Antithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy Arch Intern Med 152 1992 317 320
434. G.F.V. Tempelhoff, M. Dietrich, G. Hommel Blood coagulation during adjuvant epirubicin cyclophosphamide chemotherapy in patients with primary operable breast cancer J Clin Oncol 14 1996 2560 2568
435. O. Bairy, U. Cabbay, D. Blickstein Levels of protein C and S do not decline subsequent to first line chemotherapy in lymphoma patients Hematol Oncol 15 1997 121 127
436. M. Jaattela Biologic activities and mechanisms of action of tumor necrosis factor-alpha/cachexin Lab Invest 64 1991 724 742
437. N.D. Bevilacqua, J.S. Pober, G.R. Majeau Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium Characterization and comparison with the actions of interleukin 1 Proc Natl Acad Sci USA 83 1986 4533 4537
438. L. Tanaka, M. Imamura, M. Kasai Rapid analysis of tumor necrosis factor-alpha MRNA expression during veno-occlusive disease of the liver after allogeneic bone marrow transplantation Transplantation 55 1993 430 433
439. R.L. Schilsky, T. Anderson Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin Ann Intern Med 90 1979 929 931
440. P.D.N.W. Turiapaty, B.M. Altur Magnesium deficiency produces spasms of coronary arteries Relationship to etiology of sudden death ischemic heart disease Science 280 1980 198 200
441. B.M. Altura, B.T. Altura, A. Gebrewold Magnesium deficiency and hypertension Correlation between magnesium-deficient diets and microcirculatory changes in situ Science 223 1984 1315 1317
442. C.S. Rosenfield, L.E. Broder Cisplatin-induced autonomic neuropathy Cancer Treat Rep 68 1984 659 660
443. S.W. Hansen Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer Br Med J 300 1990 511 512
444. S.M. Carmichael, L. Eagieton, C.R. Ayers Orthostatic hypotension during vincristine therapy Arch Intern Med 126 1970 290 293
445. N.J. Dibella Vincristine-induced orthostatic hypotension A prospective clinical study Cancer Treat Rep 64 1980 359 360
446. E. Roca, E. Bruera, P.M. Politi Vinca alkaloid-induced cardiovascular autonomic neuropathy Cancer Treat Rep 69 1985 149 151
447. H.E. Hivomen, T.T. Sahni, E. Heinonen Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy Cancer 64 1989 801 805